Answers are grounded in this paper and cite their sources.
Objective Galectin-3, reflecting cardiac fibrosis, is a promising biomarker in early detection of heart failure with preserved ejection fraction (HFpEF). We aimed to clarify the clinical utility of galectin-3 levels in the diagnosis of HFpEF and to compare galectin-3 with N-terminal pro-brain-type natriuretic peptide (NT-proBNP) levels.Methods and results The study included 44 HFpEF patients (mean age 60 ± 6.78 years, 24 men) and 38 control subjects (mean age 57 ± 8.98 years, 20 men). Galectin-3 and NT-proBNP levels were assessed by the ELISA kits. The receiver operating characteristics (ROC) curve was used to examine the diagnostic performance of galectin-3 and NT-proBNP in HFpEF. Galectin-3 and NT-proBNP levels were significantly increased in patients with HFpEF compared to controls [5.35 ng/ml (0.86 – 14.90) vs 0.51 ng/ml (0.15 – 1.71) P< 0.0001, 617.75 ± 271.30 pg/ml vs 66.35 ± 54.01 pg/ml P< 0.0001, respectively]. Galectin-3 correlated with NT-proBNP, left atrial volume index, left ventricular mass index, and E/E’ (r = 0.90, P< 0.0001; r = 0.75, P= 0.0001; r = 0.86, P= 0.0001; r = 0.80, P= 0.0001; respectively). The area under the ROC curve was 0.98 for galectin-3 and 1.0 for NT-proBNP.Conclusions Our results support that, in addition to NT-proBNP, galectin-3 is also a valuable biomarker for the diagnosis of patients with HFpEF.
No takes yet. Share an insight, caveat, or question.
Polat et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: